Goldman Sachs
KRBP

Goldman Sachs’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

Goldman Sachs’s Portfolio KRBP Stock Details KRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-370
Closed -$5K – 6730
2022
Q2 		$5K Buy
+370
New +$5.84K ﹤0.01% 6346

Other funds holding KRBP

ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return

Goldman Sachs's KRBP Position: Q3 2022 in Review

Goldman Sachs sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q3 2022, closing a stake of 370 shares — an estimated $5K sold.

Goldman Sachs first reported a position in KRBP in Q2 2022 and held it in 1 quarter. The position peaked at $5K in Q2 2022. 16 funds tracked by Wall St. Rank hold KRBP as of Q3 2022.

  • Goldman Sachs reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Goldman Sachs sold 370 Kiromic BioPharma, Inc. Common Stock shares in Q3 2022, an estimated $5K.
  • Goldman Sachs first reported a position in Kiromic BioPharma, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Goldman Sachs's Kiromic BioPharma, Inc. Common Stock position peaked at $5K in Q2 2022.
  • 16 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q3 2022.

Based on Goldman Sachs's 13F filing for Q3 2022, filed 14 Nov 2022.